Chlorpheniramine maleate; hydrocodone bitartrate - Generic Drug Details

What are the generic sources for chlorpheniramine maleate; hydrocodone bitartrate and what is the scope of patent protection?

Chlorpheniramine maleate; hydrocodone bitartrate is the generic ingredient in four branded drugs marketed by Acella, Tris Pharma Inc, Persion, Mayne Pharma Inc, Padagis Us, and Sciegen Pharms, and is included in eight NDAs. Additional information is available in the individual branded drug profile pages.

Summary for chlorpheniramine maleate; hydrocodone bitartrate

US Patents:	0
Tradenames:	4
Applicants:	6
NDAs:	8
DailyMed Link:	chlorpheniramine maleate; hydrocodone bitartrate at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for chlorpheniramine maleate; hydrocodone bitartrate

D04AA	Antihistamines for topical use
D04A	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D04	ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
D	Dermatologicals

R05DA	Opium alkaloids and derivatives
R05D	COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R05	COUGH AND COLD PREPARATIONS
R	Respiratory system

R06AB	Substituted alkylamines
R06A	ANTIHISTAMINES FOR SYSTEMIC USE
R06	ANTIHISTAMINES FOR SYSTEMIC USE
R	Respiratory system

US Patents and Regulatory Information for chlorpheniramine maleate; hydrocodone bitartrate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Persion	ZUTRIPRO	chlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride	SOLUTION;ORAL	022439-001	Jun 8, 2011		DISCN	Yes	No
Acella	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate; hydrocodone bitartrate	SOLUTION;ORAL	206891-001	Jun 9, 2017		DISCN	No	No
Mayne Pharma Inc	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE	chlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride	SOLUTION;ORAL	205657-001	Aug 3, 2015		DISCN	No	No
Sciegen Pharms	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE	chlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride	SOLUTION;ORAL	206660-001	May 15, 2017		DISCN	No	No
Padagis Us	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE	chlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride	SOLUTION;ORAL	204627-001	Apr 29, 2014		RX	No	Yes
Tris Pharma Inc	HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE	chlorpheniramine maleate; hydrocodone bitartrate	SOLUTION;ORAL	206438-001	Jan 27, 2015		DISCN	No	No
Tris Pharma Inc	HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE	chlorpheniramine maleate; hydrocodone bitartrate; pseudoephedrine hydrochloride	SOLUTION;ORAL	203838-001	Nov 26, 2014		DISCN	No	No

Market and Financial Trajectory for Chlorpheniramine Maleate and Hydrocodone Bitartrate

Last updated: February 20, 2026

What are the current market dynamics for chlorpheniramine maleate?

Chlorpheniramine maleate is an antihistamine primarily used to treat allergy symptoms such as runny nose, sneezing, and itching. It has a broad presence in over-the-counter (OTC) medicines worldwide.

Market Size and Revenue

• Estimated global OTC allergy medication market valued at $5.9 billion in 2022.
• Chlorpheniramine-based products account for approximately 12-15% of this segment, translating roughly to $700 million annually.
• Growth is driven by increased allergy prevalence, especially in urbanized regions with higher pollution levels.

Competitive Landscape

• Generic versions dominate the market.
• Main brand competitors include Chlor-Trimeton (Johnson & Johnson), and others marketed through local pharmaceutical companies.
• Limited innovation due to its age, with most activity focused on formulations and combination drugs.

Regulatory and Supply Considerations

• Widely approved across global markets with minimal regulatory hurdles.
• Supply chains are stable; key manufacturing centers are in North America, Europe, and Asia.

Market Challenges

• Growing consumer preference for newer antihistamines with fewer sedative effects.
• Rising awareness about side effects may reduce OTC sales.

What are the market dynamics for hydrocodone bitartrate?

Hydrocodone bitartrate is an opioid analgesic and cough suppressant mainly prescribed for pain management and cough suppression. It faces a more complex regulatory and market environment.

Market Size and Revenue

• The global opioid analgesics market surpassed $12 billion in 2022.
• Hydrocodone contributes roughly 25-30% of North America’s prescription opioid market, valued approximately at $4 billion in the region.
• Pharmaceutical revenues are declining in some regions due to regulatory restrictions but remain robust in areas with less strict controls.

Regulatory Landscape

• Considered a Schedule II controlled substance in the U.S. since 2014.
• Stringent regulations in Europe, with many countries phasing out or severely restricting hydrocondone prescriptions.
• The opioid crisis has driven policy shifts, pushing for reduced prescriptions and increased detoxification programs.

Market Trends

• Prescriptions in the U.S. peaked around 2012 and have declined by approximately 20% since then.
• Demand persists in pain management, but market growth is limited by regulatory constraints.
• The emergence of abuse-deterrent formulations intends to mitigate misuse.

Competitive Environment

• Dominated by a few big pharmaceutical firms with extensive distribution channels.
• Generic formulations are prevalent, holding over 70% of market share.
• New formulations with abuse deterrence are increasingly replacing older versions.

Key Challenges

• Regulatory restrictions reduce prescribing options.
• Increasing pressure to curtail opioid use due to addiction concerns.
• Liability and litigation risks are rising.

What are the implications for R&D investments?

• Chlorpheniramine maleate remains a mature product with little R&D activity; investment is concentrated in formulations and combination therapies.
• Hydrocodone's market prospects are shrinking, but innovations focus on abuse-deterrent technologies and alternative pain management solutions.
• Regulatory hurdles pose significant risk for novel formulations or new uses.

Financial outlook

Drug	Revenue Estimates (2022)	Growth Drivers	Challenges
Chlorpheniramine maleate	~$700 million	OTC demand, stable supply, generic competition	Consumer shift toward newer antihistamines
Hydrocodone bitartrate	~$4 billion (North America)	Persistent pain management needs, abuse deterrence	Regulatory restrictions, declining prescriptions

Geographical considerations

Region	Key Market Features	Regulatory Status
North America	Largest hydrocodone market; OTC chlorpheniramine	Strict opioid controls; OTC chlorpheniramine widely available
Europe	Limited hydrocodone use; OTC chlorpheniramine	Tight opioid regulations; OTC options available
Asia-Pacific	Growing demand for allergy meds; less regulation for opioids	Easier access; rising prescription rates for antihistamines

Key Takeaways

• Chlorpheniramine maleate retains a stable OTC market, with limited growth prospects.
• Hydrocodone's market is shrinking in regions with strong regulations but remains significant in certain markets due to chronic pain management needs.
• Regulatory environments strongly influence market size and R&D focus, especially for hydrocodone.
• Innovation is minimal for chlorpheniramine but focused on abuse-deterrent formulations for hydrocodone.
• Supply chains remain stable, but market growth depends heavily on regulatory and societal factors.

FAQs

1. Will chlorpheniramine maleate see new formulations or uses?

Limited. Market is saturated with generic formulations; R&D focuses on combination drugs rather than novel formulations.

2. How will regulatory changes impact hydrocodone sales?

Tighter regulations reduce prescribing. Abuse-deterrent formulations aim to address misuse but do not significantly increase overall sales.

3. Are there new developments in abuse-deterrent opioids?

Yes. Several formulations with tamper-resistant features are approved or in development, aiming to reduce misuse.

4. Can OTC demand for chlorpheniramine increase in emerging markets?

Possible, as allergy awareness rises and OTC access expands, but growth is constrained by demographic shifts toward newer antihistamines.

5. What are the alternatives to hydrocodone for pain management?

Non-opioid analgesics like NSAIDs, acetaminophen, and emerging modalities like nerve blocks and implantable pain devices.

References

1. MarketsandMarkets. (2023). OTC allergy medication market analysis.
2. IQVIA. (2022). Global opioid market report.
3. U.S. Food and Drug Administration. (2014). Rescheduling of hydrocodone products.
4. European Medicines Agency. (2022). Opioid regulation policy updates.
5. Statista. (2023). Prescription drug sales data by region.